2367 Stock Overview
An investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Giant Biogene Holding Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$51.95 |
| 52 Week High | HK$58.00 |
| 52 Week Low | HK$28.75 |
| Beta | 0.70 |
| 1 Month Change | 4.21% |
| 3 Month Change | 39.46% |
| 1 Year Change | 56.48% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 94.57% |
Recent News & Updates
Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 20
Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%
Aug 21Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?
Aug 09Recent updates
Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 20Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%
Aug 21Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?
Aug 09Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear
Jul 01Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?
Apr 17Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings
Mar 28Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
Mar 27Do Giant Biogene Holding's (HKG:2367) Earnings Warrant Your Attention?
Dec 24Shareholder Returns
| 2367 | HK Personal Products | HK Market | |
|---|---|---|---|
| 7D | 3.3% | 3.3% | -0.9% |
| 1Y | 56.5% | 19.8% | 19.2% |
Return vs Industry: 2367 exceeded the Hong Kong Personal Products industry which returned 20.4% over the past year.
Return vs Market: 2367 exceeded the Hong Kong Market which returned 18.4% over the past year.
Price Volatility
| 2367 volatility | |
|---|---|
| 2367 Average Weekly Movement | 8.3% |
| Personal Products Industry Average Movement | 7.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.7% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 2367 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2367's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,512 | Jianya Yan | www.xajuzi.com |
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People’s Republic of China. It also manufactures rare ginsenosides technology-based functional foods; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional foods primarily under the Comfy, Collgene, Keyu, and SKIGIN brands.
Giant Biogene Holding Co., Ltd. Fundamentals Summary
| 2367 fundamental statistics | |
|---|---|
| Market cap | HK$52.43b |
| Earnings (TTM) | HK$1.89b |
| Revenue (TTM) | HK$4.76b |
27.8x
P/E Ratio11.0x
P/S RatioIs 2367 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2367 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.46b |
| Cost of Revenue | CN¥769.50m |
| Gross Profit | CN¥3.69b |
| Other Expenses | CN¥1.92b |
| Earnings | CN¥1.77b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.75 |
| Gross Margin | 82.74% |
| Net Profit Margin | 39.65% |
| Debt/Equity Ratio | 0% |
How did 2367 perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield24%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 03:55 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Giant Biogene Holding Co., Ltd. is covered by 27 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Junhao Fan | China International Capital Corporation Limited |
| Zhuonan Xu | China International Capital Corporation Limited |
| Yishan Li | China Merchants Securities (HK) Co., Ltd |